文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

免疫抑制联合艾曲泊帕治疗重型再生障碍性贫血的长期结局:2期研究

Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
PubMed 文献 · Blood · 2022-01-01

该2期研究纳入178例重型再生障碍性贫血患者,评估标准免疫抑制联合艾曲泊帕的长期结局。中位随访4年,应答者累积复发率39%,全部患者克隆演化率15%,高危克隆演化5.7%且总生存更差。复发与高危演化发生率未高于历史对照,但发生时间更早。

要点

  • 应答者4年累积复发率39%,多发生于环孢素减量或停用及艾曲泊帕停药后。
  • 全部患者4年克隆演化率15%,高危演化(髓系恶性肿瘤或7号染色体异常)占5.7%。
  • 高危克隆演化者总生存更差;复发与高危演化发生率未高于历史对照但发生更早。

核心结论

  • 免疫抑制联合艾曲泊帕治疗重型再生障碍性贫血的复发与克隆演化发生率未高于历史对照,但发生时间更早。

研究设计与样本

  • 2期试验的次要终点分析,2012至2020年纳入178例重型再生障碍性贫血患者,中位随访4年。

主要发现

  • 应答者累积复发率39%,全部患者克隆演化率15%,高危克隆演化占5.7%。
  • 复发发生于环孢素减量及艾曲泊帕停药后6个月,以及环孢素停用后2年。
  • 大多数复发患者接受治疗剂量环孢素±艾曲泊帕再治疗,三分之二应答。
  • 高危克隆演化患者总生存更差。
  • 复发与高危演化发生率未高于历史对照,但中位发生时间更早。

临床怎么用

  • 接受免疫抑制联合艾曲泊帕治疗的重型再生障碍性贫血患者需长期监测复发与克隆演化。
  • 环孢素减量或停用及艾曲泊帕停药后应警惕复发,复发后再治疗仍可能有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with severe aplastic anemia (SAA) are either treated with bone marrow transplant (BMT) or immunosuppression (IST) depending on their age, comorbidities, and available donors. In 2017, our phase 2 trial reported improved hematologic responses with the addition of eltrombopag (EPAG) to standard IST for SAA when compared with a historical cohort treated with IST alone. However, the rates and characteristics of long-term complications, relapse, and clonal evolution, previously described in patients treated with IST alone, are not yet known with this new regimen, IST and EPAG. Patients were accrued from 2012 to 2020, with a total of 178 subjects included in this secondary endpoint analysis. With double the sample size and a much longer median follow-up (4 years) since the original publication in 2017, we report a cumulative relapse rate of 39% in responding patients who received cyclosporine (CSA) maintenance and clonal evolution of 15% in all treated patients at 4 years. Relapse occurred at distinct timepoints: after CSA dose reduction and EPAG discontinuation at 6 months, and after 2 years when CSA was discontinued. Most relapsed patients were retreated with therapeutic doses of CSA +/- EPAG, and two-thirds responded. Clonal evolution to a myeloid malignancy or chromosome 7 abnormality (high-risk) was noted in 5.7% of patients and conferred a poorer overall survival. Neither relapse nor high-risk evolution occurred at a higher rate than was observed in a historical comparator cohort, but the median time to both events was earlier in IST and EPAG treated patients. This trial was registered at www.clinicaltrials.gov as #NCT01623167.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Patel BA, Groarke EM, Lotter J, et al. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood. 2022. PMID: 34525188. doi:10.1182/blood.2021012130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。